Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320 is registered in ClinicalTrials.gov with Revolution Medicines, Inc. as lead sponsor.

NCT NCT06625320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06625320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Lead sponsor
Revolution Medicines, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 16, 2024
Completion date
December 31, 2027
Enrollment
500 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, pdac, pdac - pancreatic ductal adenocarcinoma